NAS:INCY (USA) Also Trade In: Austria Brazil Germany Mexico UK

Incyte Corp $ 85.42 0.88 (1.04%)

On watch
Volume:
840,961
Avg Vol (1m):
1,171,632
Market Cap $:
18.71 Bil
Enterprise Value $:
17.03 Bil
P/E (TTM):
0.00
P/B:
7.82
Warning! GuruFocus has detected 3 Severe warning signs with INCY. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Incyte Corp () from 1993 to Dec 02 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Incyte stock (INCY) PE ratio as of Dec 02 2020 is 0. More Details

Incyte PE Ratio (TTM) Chart

EMBED

Incyte PE Ratio (TTM) Historical Data

Total 1283
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Incyte PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2020-12-020.0 2020-09-300.0
2020-12-010.0 2020-09-290.0
2020-11-300.0 2020-09-280.0
2020-11-270.0 2020-09-250.0
2020-11-260.0 2020-09-240.0
2020-11-250.0 2020-09-230.0
2020-11-240.0 2020-09-220.0
2020-11-230.0 2020-09-210.0
2020-11-200.0 2020-09-180.0
2020-11-190.0 2020-09-170.0
2020-11-180.0 2020-09-160.0
2020-11-170.0 2020-09-150.0
2020-11-160.0 2020-09-140.0
2020-11-130.0 2020-09-110.0
2020-11-120.0 2020-09-100.0
2020-11-110.0 2020-09-090.0
2020-11-100.0 2020-09-080.0
2020-11-090.0 2020-09-070.0
2020-11-060.0 2020-09-040.0
2020-11-050.0 2020-09-030.0
2020-11-040.0 2020-09-020.0
2020-11-030.0 2020-09-010.0
2020-11-020.0 2020-08-310.0
2020-10-300.0 2020-08-280.0
2020-10-290.0 2020-08-270.0
2020-10-280.0 2020-08-260.0
2020-10-270.0 2020-08-250.0
2020-10-260.0 2020-08-240.0
2020-10-230.0 2020-08-210.0
2020-10-220.0 2020-08-200.0
2020-10-210.0 2020-08-190.0
2020-10-200.0 2020-08-180.0
2020-10-190.0 2020-08-170.0
2020-10-160.0 2020-08-140.0
2020-10-150.0 2020-08-130.0
2020-10-140.0 2020-08-120.0
2020-10-130.0 2020-08-110.0
2020-10-120.0 2020-08-100.0
2020-10-090.0 2020-08-070.0
2020-10-080.0 2020-08-060.0
2020-10-070.0 2020-08-050.0
2020-10-060.0 2020-08-040.0
2020-10-050.0 2020-08-030.0
2020-10-020.0 2020-07-310.0
2020-10-010.0 2020-07-300.0

Incyte PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 541714 NAICS : 8731
Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.